Quick Answer
Lantern Pharma Inc. reported Operating Income of -$17.98 million for fiscal year 2025.
Lantern Pharma Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$17.98M | +19.1% |
| 2024 | -$22.22M | -24.3% |
| 2023 | -$17.88M | -23.9% |
| 2022 | -$14.43M | -14.6% |
| 2021 | -$12.59M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$4.35M | +16.0% | +6.5% |
| June 30, 2025 | -$4.65M | +14.0% | +2.6% |
| March 31, 2025 | -$4.77M | +16.7% | +7.8% |
| September 30, 2024 | -$5.18M | -47.0% | +4.2% |
| June 30, 2024 | -$5.41M | -4.2% | +5.6% |
| March 31, 2024 | -$5.73M | -33.7% | -62.7% |
| September 30, 2023 | -$3.52M | -64.3% | +32.1% |
| June 30, 2023 | -$5.19M | -18.1% | -21.1% |
- Lantern Pharma Inc. showed an increase of +19.1% in Operating Income compared to the prior fiscal year.
- Over the 2021–2025 period, Lantern Pharma Inc.’s operating income has declined by 42.8% (from -$12.59 million to -$17.98 million).
- The most recent figure is from Lantern Pharma Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: